Michael Miller
A5015234811- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Reconstructive Surgery and Microvascular Techniques
- Fatty Acid Research and Health
- Cancer, Lipids, and Metabolism
- Breast Implant and Reconstruction
- Lipid metabolism and disorders
- Reconstructive Facial Surgery Techniques
- Diet and metabolism studies
- Liver Disease Diagnosis and Treatment
- Cholesterol and Lipid Metabolism
- Cardiovascular Function and Risk Factors
- Bone Tissue Engineering Materials
- Diet, Metabolism, and Disease
- Acute Myocardial Infarction Research
- Eicosanoids and Hypertension Pharmacology
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Disease and Adiposity
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Nutritional Studies and Diet
- Peroxisome Proliferator-Activated Receptors
- Anesthesia and Pain Management
- Bone fractures and treatments
University of Pennsylvania
2022-2025
Western University
2017-2025
New England College of Optometry
2024-2025
Optum (United States)
2024-2025
Hospital of the University of Pennsylvania
1997-2024
Cincinnati Children's Hospital Medical Center
2024
Johns Hopkins University
2008-2024
Johns Hopkins Medicine
1990-2024
Children’s Health Research Institute
2018-2024
Philadelphia VA Medical Center
2022-2024
Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers levels, but data needed to determine its effects on
Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced algorithms to identify now exist, but systematic attempts combine and optimize them on large datasets are few. We report a PanCancer PanSoftware analysis spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) using 26 computational tools catalog driver genes mutations. 299 with implications regarding their anatomical sites cancer/cell types. Sequence- structure-based...
Aneuploidy, whole chromosome or arm imbalance, is a near-universal characteristic of human cancers. In 10,522 cancer genomes from The Cancer Genome Atlas, aneuploidy was correlated with TP53 mutation, somatic mutation rate, and expression proliferation genes. Aneuploidy anti-correlated immune signaling genes, due to decreased leukocyte infiltrates in high-aneuploidy samples. Chromosome arm-level alterations show cancer-specific patterns, including loss 3p squamous We applied genome...
Treatment added to statin monotherapy further modify the lipid profile may include combination therapy either raise high-density lipoprotein (HDL) cholesterol level or lower low-density (LDL) level.We enrolled patients who had coronary heart disease a risk equivalent, were receiving long-term therapy, and in whom an LDL under 100 mg per deciliter (2.6 mmol liter) HDL 50 for men 55 women (1.3 1.4 liter, respectively) been achieved. The randomly assigned receive extended-release niacin (target...
Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers null mutation (R19X) gene encoding apoC-III ( APOC3 ) and, as result, express half amount present noncarriers. Mutation compared with noncarriers had lower fasting postprandial serum triglycerides, higher levels HDL-cholesterol LDL-cholesterol. Subclinical...
Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy bococizumab in patients at high cardiovascular risk.In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned 27,438 combined receive (at dose 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was...
Hotspot mutations in splicing factor genes have been recently reported at high frequency hematological malignancies, suggesting the importance of RNA cancer. We analyzed whole-exome sequencing data across 33 tumor types The Cancer Genome Atlas (TCGA), and we identified 119 with significant non-silent mutation patterns, including over-representation, recurrent loss function (tumor suppressor-like), or hotspot profile (oncogene-like). Furthermore, analysis revealed altered events associated...
Hypertriglyceridemia (triglycerides 200-499 mg/dL) is relatively common in the United States, whereas more severe triglyceride elevations (very high triglycerides, ≥500 are far less frequently observed. Both becoming increasingly prevalent States and elsewhere, likely driven large part by growing rates of obesity diabetes mellitus. In a 2002 American Heart Association scientific statement, omega-3 fatty acids (n-3 FAs) eicosapentaenoic acid (EPA) docosahexaenoic (DHA) were recommended (at...
Background Platelet activation and aggregation may be key components of thrombolytic failure to restore maintain perfusion in acute myocardial infarction. We performed a placebo-controlled, dose-ranging trial Integrilin, potent inhibitor platelet aggregation, with heparin, aspirin, accelerated alteplase. Methods Results assigned 132 patients 2:1 ratio receive bolus continuous infusion one six Integrilin doses or placebo. Another 48 were randomized 3:1, double-blind fashion the highest dose...
Highlights•Classification of metabolic expression subtypes in 33 TCGA cancer types•Metabolic show consistent prognostic patterns across types•Analysis master regulators suggesting therapeutic targets•Metabolic associated with sensitivity to drugs clinical useSummaryMetabolic reprogramming provides critical information for oncology. Using molecular data 9,125 patient samples from The Cancer Genome Atlas, we identified tumor types based on mRNA seven major processes and assessed their...
In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of ischemic events, including cardiovascular death, among patients with elevated triglycerides receiving statins. These are at for not only first but also subsequent events.Pre-specified analyses determined extent to which total events.REDUCE-IT (Reduction Cardiovascular Events Icosapent Ethyl-Intervention Trial) randomized 8,179 statin-treated ≥135 and <500 mg/dl (median baseline 216 mg/dl) low-density...
REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) reported a 25% relative risk reduction in major adverse cardiovascular events with use icosapent ethyl compared pharmaceutical grade mineral oil. The mechanisms underlying this benefit remain uncertain. We explored whether treatment allocation might affect series biomarkers pathways known to associate atherosclerosis risk.Serum levels interleukin-1β, interleukin-6, high-sensitivity C-reactive protein,...